Skip to content

Towards Restoring the Physiological Inhibition of Airway Narrowing in Asthma

Towards Restoring the Physiological Inhibition of Airway Narrowing in Asthma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00279136
Enrollment
36
Registered
2006-01-19
Start date
2004-09-30
Completion date
2006-03-31
Last updated
2006-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Chronic Obstructive Pulmonary Disease

Keywords

Bronchial hyperresponsiveness,, lung function,, airway inflammation,, deep inspiration,, bronchial biopsies, airway smooth muscle

Brief summary

Asthma and COPD are characterized by airway narrowing. The most potent, physiological mechanism leading to bronchodilation is taking a deep inspiration. This protects healthy subjects against bronchoconstrictive stimuli, and reverses pre-existing bronchoconstriction. However, the deep breath-induced bronchoprotection and -bronchodilation is impaired in asthma. We questioned whether this is specific for asthma (in comparison to COPD), and whether this is associated with bronchial inflammation and -remodelling. The study is a two-groups comparison, of physiological and pathological disease markers, obtained by methacholine challenges, monitoring airways resistance, and by taking bronchial biopsies.

Detailed description

Rationale. Asthma is associated with variable airways obstruction and airways inflammation. It is generally assumed that inflammatory mechanisms are promoting airway narrowing, by stimulating airway smooth muscle and by geometrical changes of the airway wall. Healthy subjects are very effectively protected against stimuli of airway narrowing, by mechanisms that are apparently failing in asthma. The most potent inhibitor of airway narrowing in healthy subjects is taking a deep inspiration. This prevents and reverses bronchoconstriction (DI-induced bronchoprotection and -bronchodilation, respectively), which is less effective or absent in asthma. The DI-induced inhibition of airway narrowing in normal subjects is presumably due to relaxation of smooth muscle after mechanical stretch or to the release of relaxant mediators (such as endogenous NO). Such mechanisms might have become impaired in asthma, secondary to e.g. mechanical uncoupling of smooth muscle from the surrounding parenchyma (e.g. by congestion or edema), by altered structure and function of airway smooth muscle, and/or by reduced inhibitory mediator release. It can be postulated that the impaired response to deep inspiration is a central pathophysiological feature of asthma at all ages. Therefore, we believe that it is imperative to address this, by identifying and restoring these inhibitory pathways in patients with asthma. Hypotheses. We hypothesize that DI-induced bronchoprotection and -broncho¬dilation: 1. are associated with cellular and morphological features of airways inflammation, 2. can be restored by deep insufflation rather than deep inspiration, and by pharmacological interventions aimed to reduce microvascular congestion or to increase endogenous nitric oxide synthesis.. Design and methods. To examine to what extent DI-responses differ between asthma and COPD in adulthood, and whether this is associated with features of airways inflammation and changes in smooth muscle function. 12 Adult patients with asthma and 12 with COPD will undergo single-dose methacholine challenge, with prohibition of DI's or 5 DI's prior to challenge in a cross-over design, measuring airways resistance. On a separate day bronchial biopsies will obtained with immunohistochemistry for inflammatory cell markers, vascularity, microvascular leakage, myosin light chain kinase, NO-synthases, and arginase.

Interventions

None listed

Sponsors

The Netherlands Asthma Foundation
CollaboratorOTHER
Leiden University Medical Center
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Asthma according to GINA criteria (www.ginasthma.org) * COPD according to GOLD criteria (www.goldcopd.org)

Exclusion criteria

* nonsmoking * inhaled or oral steroid therapy

Countries

Netherlands

Contacts

Primary ContactPeter J. Sterk, MD, PhD
p.j.sterk@lumc.nl+31 71 526 3578
Backup ContactAnnelies M. Slats, MD
a.m.slatts@lumc.nl+31 71 526 3734

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026